New Collaborative Platform FlowMod Aims to Transform Heart Failure Treatment
In a promising development for heart health, Ajax Health, backed by KKR, has unveiled FlowMod, a new platform aimed at revolutionizing treatment options for heart failure. This initiative is a collaborative effort involving Boston Scientific Corporation, which lends its extensive intellectual property resources to this exciting venture. Heart failure is a condition that affects the heart's pumping ability, currently impacting over 64 million individuals worldwide. With FlowMod, the goal is to expedite the development, clinical validation, and regulatory approval processes for innovative heart failure treatments.
Duke Rohlen, the Chief Executive Officer of Ajax Health, expressed his enthusiasm about this venture, commenting, "Following our recent interaction with Boston Scientific, we are excited to embark on this new journey in treating heart failure. We believe this collaboration will yield significant benefits for the millions diagnosed with this condition each year." This reflects a commitment not just to innovation, but to improving the quality of care available to patients suffering from cardiovascular diseases.
The strategic alliance leverages the strengths of its founders, ensuring that they are well-positioned to address the challenges faced by physicians and their patients in managing heart failure. The intention is to create a distinctive solution that redefines treatment protocols for this prevalent ailment.
KKR's involvement through its KKR Health Care Strategic Growth Fund II, which is focused on high-growth healthcare companies, plays a vital role in the establishment of FlowMod. This fund, amounting to $4.0 billion, seeks to invest in companies that demonstrate significant promise in transforming health care practices. Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR, emphasized the importance of this collaboration, stating, "We are excited to join forces with Ajax Health and Boston Scientific. Our aim is to innovate alongside leading partners, pushing the boundaries of medical technology for the benefit of cardiovascular patients around the world."
Dr. Philippe Marco, who will steer FlowMod as its CEO, brings invaluable experience from his previous roles at Epix Therapeutics and CV Ingenuity—both companies have successfully gained pre-market approvals for groundbreaking cardiovascular devices. Dr. Marco conveyed his anticipation for the journey ahead, stating, "I am looking forward to collaborating with the leadership teams of Ajax Health and KKR once again. Together, we aim to produce significant advancements in how heart failure is treated, building on the innovations previously established by Boston Scientific."
As the hearts of millions depend on effective treatments, the formation of FlowMod exemplifies a robust response to an urgent global health issue. The strategic ties between Ajax Health, KKR, and Boston Scientific highlight a concerted approach to leverage existing technologies while fostering innovation within the healthcare industry. With the potential to reshape treatment methodologies for heart failure, FlowMod stands as a beacon of hope for patients, medical professionals, and the broader healthcare community.
Through this collaboration, we can anticipate a future where advances in technology harmonize with patient care, creating more effective and specialized treatment modalities for heart failure. As efforts intensify at FlowMod, the collective experience of its founders and partners will likely yield transformative results in the fight against cardiovascular disease—a journey that promises to touch many lives, paving the way for a healthier future.
Duke Rohlen, the Chief Executive Officer of Ajax Health, expressed his enthusiasm about this venture, commenting, "Following our recent interaction with Boston Scientific, we are excited to embark on this new journey in treating heart failure. We believe this collaboration will yield significant benefits for the millions diagnosed with this condition each year." This reflects a commitment not just to innovation, but to improving the quality of care available to patients suffering from cardiovascular diseases.
The strategic alliance leverages the strengths of its founders, ensuring that they are well-positioned to address the challenges faced by physicians and their patients in managing heart failure. The intention is to create a distinctive solution that redefines treatment protocols for this prevalent ailment.
KKR's involvement through its KKR Health Care Strategic Growth Fund II, which is focused on high-growth healthcare companies, plays a vital role in the establishment of FlowMod. This fund, amounting to $4.0 billion, seeks to invest in companies that demonstrate significant promise in transforming health care practices. Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR, emphasized the importance of this collaboration, stating, "We are excited to join forces with Ajax Health and Boston Scientific. Our aim is to innovate alongside leading partners, pushing the boundaries of medical technology for the benefit of cardiovascular patients around the world."
Dr. Philippe Marco, who will steer FlowMod as its CEO, brings invaluable experience from his previous roles at Epix Therapeutics and CV Ingenuity—both companies have successfully gained pre-market approvals for groundbreaking cardiovascular devices. Dr. Marco conveyed his anticipation for the journey ahead, stating, "I am looking forward to collaborating with the leadership teams of Ajax Health and KKR once again. Together, we aim to produce significant advancements in how heart failure is treated, building on the innovations previously established by Boston Scientific."
As the hearts of millions depend on effective treatments, the formation of FlowMod exemplifies a robust response to an urgent global health issue. The strategic ties between Ajax Health, KKR, and Boston Scientific highlight a concerted approach to leverage existing technologies while fostering innovation within the healthcare industry. With the potential to reshape treatment methodologies for heart failure, FlowMod stands as a beacon of hope for patients, medical professionals, and the broader healthcare community.
Through this collaboration, we can anticipate a future where advances in technology harmonize with patient care, creating more effective and specialized treatment modalities for heart failure. As efforts intensify at FlowMod, the collective experience of its founders and partners will likely yield transformative results in the fight against cardiovascular disease—a journey that promises to touch many lives, paving the way for a healthier future.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.